Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians and patients with high-value in vitro diagnostic oncology products.Veridex’s products will significantly benefit patients through earlier disease detection, and will enable personalized strategies to improve patient management and outcomes.

Provides fully integrated contract manufacturing services to medical device manufacturers worldwide in the cardiovascular, endoscopy and orthopedic markets

zPREDICTA’s bio-simulation technology combines biology with automation and computation to automate drug development. zPREDICTA's bio-simulation platform enables pharma to rapidly identify drug candidates that will be effective in patients. r-Organ is a set of next generation 3D culture models that provide 1-to-1 reconstruction of human tissue microenvironment in an organ- and disease-specific manner allowing accurate prediction of drug response. Utilizing r-Organ technology, zPREDICTA is mapping cellular behavior in response to anticancer drugs.

Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company is headquartered in Palo Alto, CA.

Janssen Diagnostics LLC, a subsidiary of Johnson & Johnson, is an American company located in Raritan, NJ. The firm designs and manufacture special machinery for the pharmaceutical industry.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

The Dutch Cancer Society (DCS; in Dutch: 'KWF Kankerbestrijding' ) is a Dutch Society committed to fight cancer by scientific research, education, patient support and fundraising in cooperation with volunteers, donors, patients, doctors and researchers. By this commitment, DCS targets less cancer, more cures and a higher quality of life for cancer patients. Its motto is, 'Everyone Deserves a Tomorrow' .

Alberta Research Council (ARC) was an Alberta government funded applied research and development (R&D) corporation. In January 2010, it was replaced, in part, by Alberta Innovates - Technology Futures . In November 2016 Alberta Innovates - Technology Futures was consolidated to form Alberta Innovates.

Urodelia SA develops immunotherapy method to treat cancer in pets. The company was founded by Nicole Rouquet, Patrick Landanger and Patrick Frayssinet in 2003 and is headquartered in Saiguede, France.

Advanced Cancer Therapeutics, LLC engages in the discovery, development, manufacture, and commercialization of cancer therapeutics. It develops a pipeline of anti-cancer products, including MIF, a macrophage migration inhibitory factor; PU27, a synthetic oligonucleotide that is used as an anticancer compound; PFKFB3, a small molecule compound; CK37, a small molecule that inhibits cell proliferation, choline kinase enzymatic activity, and tumor growth; and a vaccine for human papilloma virus, which is caused for cervical cancer. The company was founded in 2007 and is based in Louisville, Kentucky.

Shangqiu Cancer Institute, established on 1997-08-01, Business scope includes biotechnology development.Development of new drugs for preventing and treating tumors.to promote.application.Production.Sales.***

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.

Meda is an international specialty pharma company with its own sales organizations in over 55 countries and operations expanding in growth markets. Meda is the 50th largest pharmaceutical company in the world. At the end of 2012, Meda had 2,900 employees, about 1,800 of whom work in sales and marketing. Sales and marketing activities are carried out via agents in countries where Meda has no representation. Meda’s pharmaceuticals are sold in more than 120 countries. Their vision is to become a world-leading specialty pharma company with a focus on sustainable and profitable growth to provide value for their patients, shareholders and other stakeholders. They strive to be a fast-growing, innovative company that is open to different kinds of commercial models and that will be market-leading in certain therapy areas with prescription and non-prescription (Cx and OTC) products. They are dedicated to providing products that serve society by increasing the well-being and quality of life of individuals. As a company, their aim is to attract the best talent and reward their employees for outstanding performance. Maintaining their excellent reputation is vital to them.

Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

3M Innovative Properties Co. acquires and manages intellectual property right. It engages in the acquisition and ownership of the intellectual property rights to the products designed and manufactured by its parent company 3M Corporation. The company was founded on May 10, 1999 and is headquartered in Roseville, MN.